Practice parameterDrug Allergy: An Updated Practice Parameter
Section snippets
Chief Editors
Roland Solensky, MD, and David A. Khan, MD
Workgroup Contributors
I. Leonard Bernstein, MD; Gordon R. Bloomberg, MD; Mariana C. Castells, MD, PhD; Louis M. Mendelson, MD; and Michael E. Weiss, MD
Task Force Reviewers
David I. Bernstein, MD; Joann Blessing-Moore, MD; Linda Cox, MD; David M. Lang, MD; Richard A. Nicklas, MD; John Oppenheimer, MD; Jay M. Portnoy, MD; Christopher Randolph, MD; Diane E. Schuller, MD; Sheldon L. Spector, MD; Stephen Tilles, MD; and Dana Wallace, MD
Reviewers
Paul J. Dowling, MD – Kansas City, MO
Mark Dykewicz, MD – Winston-Salem, NC
Paul A. Greenberger, MD – Chicago, IL
Eric M. Macy, MD – San Diego, CA
Kathleen R. May MD – Cumberland, MD
Myngoc T. Nguyen, MD – Piedmont, CA
Lawrence B. Schwartz, MD, PhD – Richmond, VA
Contributors
The Joint Task Force has made a concerted effort to acknowledge all contributors to this parameter. If any contributors have been excluded inadvertently, the Task Force will ensure that appropriate recognition of such contributions is made subsequently.
Chief Editors
Roland Solensky, MD
Division of Allergy and Immunology
The Corvallis Clinic
Corvallis, Oregon
David A. Khan, MD
Professor of Medicine
Division of Allergy & Immunology
University of Texas Southwestern Medical Center
Dallas, Texas
Workgroup Contributors
I. Leonard Bernstein, MD
Professor of Clinical Medicine
University of Cincinnati College of Medicine
Cincinnati, Ohio
Gordon R. Bloomberg, MD
Associate Professor, Department of Pediatrics
Division of Allergy & Pulmonary Medicine
Washington University School of Medicine
Saint Louis, Missouri
Mariana C. Castells, MD, PhD
Director, Desensitization Program
Associate Director, Allergy Immunology Training Program
Brigham & Women's Hospital
Harvard Medical School
Boston, Massachusetts
Louis M. Mendelson, MD
Clinical
Task Force Reviewers
David I. Bernstein, MD
Department of Clinical Medicine, Division of Immunology
University of Cincinnati College of Medicine
Cincinnati, Ohio
Joann Blessing-Moore, MD
Department of Immunology
Stanford University Medical Center
Palo Alto, California
Linda Cox, MD
Department of Medicine
Nova Southeastern University
Davie, Florida
David M. Lang, MD
Allergy/Immunology Section, Division of Medicine
Cleveland Clinic Foundation
Cleveland, Ohio
Richard A. Nicklas, MD
Department of Medicine
George Washington Medical Center
Preface
The objective of “Drug Allergy: An Updated Practice Parameter” is to improve the care of patients by providing the practicing physician with an evidence-based approach to the diagnosis and management of adverse drug reactions. This document was developed by a Working Group under the aegis of the Joint Task Force on Practice Parameters, which has published 26 practice parameters and updated parameters for the field of allergy/immunology (these can be found online at www.jcaai.org). The 3
Classification of Adverse Reactions to Drugs
Adverse drug reactions (ADRs) result in major health problems in the United States in both the inpatient and outpatient settings. ADRs are broadly categorized into predictable (type A) and unpredictable (type B) reactions. Predictable reactions are usually dose dependent, are related to the known pharmacologic actions of the drug, and occur in otherwise healthy individuals. They are estimated to comprise approximately 80% of all ADRs. Unpredictable reactions are generally dose independent, are
References (194)
- et al.
Delayed-type hypersensitivity reaction to p-phenylenediamine is mediated by two different pathways of antigen recognition by specific alpha-beta human T-cell clones
J Allergy Clin Immunol
(2002) - et al.
Dermatologic drug reactions
Immunol Allergy Clin North Am
(2004) - et al.
Report of the penicillin study group, American Academy of Allergy
J Allergy Clin Immunol
(1971) - et al.
Penicillin skin testing in patients with a history of beta-lactam allergy
Ann Allergy Asthma Immunol
(2007) - et al.
Under-reporting of antibiotic anaphylaxis may put patients at risk
Lancet
(1999) - et al.
Safety and effectiveness of a preoperative allergy clinic in decreasing vancomycin use in patients with a history of penicillin allergy
Ann Allergy Asthma Immunol
(2006) - et al.
Detection of specific IgE to quinolones
J Allergy Clin Immunol
(2004) - et al.
Systemic allergy to human insulin and its rapid and long acting analogs: successful treatment by continuous subcutaneous insulin lispro infusion
Diabetes Metab
(2005) - et al.
Toward understanding insulin fibrillation
J Pharm Sci
(1997) - et al.
Carboplatin hypersensitivity: a 12-step protocol effective in 35 desensitizations in patients with gynecological malignancies and mast cell/IgE-mediated reactions
Gynecol Oncol
(2004)
Successful parental desensitization to paclitaxel
J Allergy Clin Immunol
Hypersensitivity reactions to chemotherapy: outcomes and safety of rapid desensitization in 413 cases
J Allergy Clin Immunol
A modified, prolonged desensitization protocol in carboplatin allergy
J Allergy Clin Immunol
Skin testing and hypersensitivity reactions to oxaliplatin
Ann Oncol
Desensitization to trimethoprim/sulfamethoxazole in HIV-infected patients
J Allergy Clin Immunol
Management of adverse reactions to prophylactic trimethoprim-sulfamethoxazole in patients with human immunodeficiency virus infection
Ann Allergy Asthma Immunol
Successful oral desensitization to trimethoprim-sulfamethoxazole in acquired immune deficiency syndrome
Ann Allergy Asthma Immunol
Trimethoprim/sulfamethoxazole incremental dose regimen in human immunodeficiency virus-infected persons
Ann Allergy Asthma Immunol
Six-hour trimethoprim-sulfamethoxazole-graded challenge in HIV-infected patients
J Allergy Clin Immunol
The effectiveness of desensitization versus rechallenge treatment in HIV-positive patients with previous hypersensitivity to TMP-SMX: a randomized multicentric study
Biomed Pharmacother
A 5-day course of oral desensitization to trimethoprim/sulfamethoxazole (T/S) in patients with human immunodeficiency virus type-1 infection who were previously intolerant to T/S
Ann Allergy Asthma Immunol
Allergy and desensitization to zidovudine in patients with acquired immunodeficiency syndrome (AIDS)
J Allergy Clin Immunol
Zidovudine-related erythroderma and successful desensitization: a case report
J Allergy Clin Immunol
HIV and drug allergy
Immunol Allergy Clin North Am
The abacavir hypersensitivity reaction: a review
Clin Ther
Intracellular cytokines may model immunoregulation of abacavir hypersensitivity in HIV-infected subjects
J Allergy Clin Immunol
Genetic variations in HLA-B region and hypersensitivity reactions to abacavir
Lancet
Delayed drug hypersensitivity reactions
Ann Intern Med
Transfection of drug-specific T-cell receptors into hybridoma cells: tools to monitor drug interaction with T-cell receptors and evaluate cross-reactivity to related compounds
Mol Pharmacol
Clinical evaluation of Pharmacia CAP System RAST FEIA amoxicilloyl and benzylpenicilloyl in patients with penicillin allergy
Allergy
Relevance of the determination of serum-specific IgE antibodies in the diagnosis of immediate beta-lactam allergy
Allergy
Flow cytometric basophil activation test: a review
J Investig Allergol Clin Immunol
The flow-cytometric determination of basophil activation induced by aspirin and other non-steroidal anti-inflammatory drugs (NSAIDs) is useful for in vitro diagnosis of the NSAID hypersensitivity syndrome
Clin Exp Allergy
Flow cytometric basophil activation test by detection of CD63 expression in patients with immediate-type reactions to betalactam antibiotics
Clin Exp Allergy
The diagnostic interpretation of basophil activation test in immediate allergic reactions to betalactams
Clin Exp Allergy
Diagnosing nonimmediate reactions to penicillins by in vivo tests
Int Arch Allergy Immunol
The use of skin testing in the investigation of cutaneous adverse drug reactions
Br J Dermatol
T-cell involvement in drug-induced acute generalized exanthematous pustulosis
J Clin Invest
Fixed drug eruption from piroxicam
J Eur Acad Dermatol Venereol
Patch testing in severe cutaneous adverse drug reactions, including Stevens-Johnson syndrome and toxic epidermal necrolysis
Contact Dermatitis
Histopathology of drug-induced exanthems: is there a role in diagnosis of drug allergy?
Curr Opin Allergy Clin Immunol
Results of the National Institute of Allergy and Infectious Diseases collaborative clinical trial to test the predictive value of skin testing with major and minor penicillin derivatives in hospitalized adults
Ann Intern Med
Clinical experience with penicillin skin testing in a large inner-city STD clinic
JAMA
The incidence of antimicrobial allergies in hospitalized patients: implications regarding prescribing patterns and emerging bacterial resistance
Ann Intern Med
Cross-reactivity and tolerability of cephalosporins in patients with immediate hypersensitivity to penicillins
Ann Intern Med
Tolerability of meropenem in patients with IgE-mediated hypersensitivity to penicillins
Ann Intern Med
Imipenem in patients with immediate hypersensitivity to penicillins
N Engl J Med
Absence of cross-reactivity between sulfonamide antibiotics and sulfonamide nonantibiotics
N Engl J Med
Cutaneous adverse reaction to ciprofloxacin: demonstration of specific lymphocyte proliferation and cross-reactivity to ofloxacin in vitro
Acta Dermato-Venereol
Fluoroquinolone-associated anaphylaxis in spontaneous adverse drug reaction reports in Germany: differences in reporting rates between individual fluoroquinolones and occurrence after first-ever use
Drug Saf
Cited by (776)
Rural Health Disparities in Allergy, Asthma, and Immunologic Diseases: The Current State and Future Direction for Clinical Care and Research
2024, Journal of Allergy and Clinical Immunology: In Practice“Antibiotic hypersensitivity reactions in Cystic Fibrosis: A thorough inspection on a stumbling block in patient care”
2024, Paediatric Respiratory ReviewsAnaphylaxis: What You Need to Know
2023, Physician Assistant ClinicsFacilitators and Barriers to Verifying Penicillin Allergies in a Veteran Nursing Home Population
2023, Journal of Allergy and Clinical Immunology: In PracticeThe 80th anniversary of Annals of Allergy, Asthma & Immunology (1943-2023)
2023, Annals of Allergy, Asthma and ImmunologyParental perspective on penicillin allergy delabeling in a pediatric emergency department
2023, Annals of Allergy, Asthma and Immunology
These parameters were developed by the Joint Task Force on Practice Parameters, representing the American Academy of Allergy, Asthma and Immunology; the American College of Allergy, Asthma and Immunology; and the Joint Council of Allergy, Asthma and Immunology.
The American Academy of Allergy, Asthma and Immunology (AAAAI) and the American College of Allergy, Asthma and Immunology (ACAAI) have jointly accepted responsibility for establishing “Drug Allergy: An Updated Practice Parameter.” This is a complete and comprehensive document at the current time. The medical environment is a changing environment, and not all recommendations will be appropriate for all patients. Because this document incorporated the efforts of many participants, no single individual, including those who served on the Joint Task Force, is authorized to provide an official AAAAI or ACAAI interpretation of these practice parameters. Any request for information about or an interpretation of these practice parameters by the AAAAI or ACAAI should be directed to the Executive Offices of the AAAAI, the ACAAI, and the Joint Council of Allergy, Asthma and Immunology. These parameters are not designed for use by pharmaceutical companies in drug promotion.
Reprint requests: Joint Council of Allergy, Asthma & Immunology, 50 N. Brockway St, #3-3, Palatine, IL 60067.